Different Positive Pressure Strategies in COPD Patients.
Study Details
Study Description
Brief Summary
Chronic obstructive pulmonary disease (COPD) is characterized by a poorly reversible airway obstruction and consequent systemic manifestations. Its high prevalence and high number of diagnosed patients has become a challenge for health services due to the costs of diagnosis and treatment of these patients. Positive pressure and aerosol therapy are preferred therapies for the management of COPD symptoms, but their effects when associated are poorly studied. The objective of this study is to compare the effects of different positive pressure strategies associated with aerosol therapy through Pulmonary Scintigraphy and Electrical Impedance Tomography (EIT) in patients with COPD in the intercrise period. This is a randomized, crossover, blinded and allocated crossover type clinical trial in which patients with moderate to severe COPD will be allocated to three intervention groups with different strategies for positive pressure associated with aerosol therapy: control group 1 nebulization), group 2 nebulization with EPAP valve and group 3 nebulization with NIV bi-level pressure mode. The radioaerosol deposition pattern will be evaluated through Pulmonary Scintigraphy and regional pulmonary ventilation through EIT.
Condition or Disease | Intervention/Treatment | Phase |
---|---|---|
|
N/A |
Study Design
Arms and Interventions
Arm | Intervention/Treatment |
---|---|
Experimental: Nebulization control intervention, will only perform nebulization; |
Device: Nebulization
For inhalation of the radioaerosol a dose of DTPA-Tc99m (methionine-labeled diethylnitriaminepentaacetic acid) with 1mCi activity, associated with 10 drops of Fenoterol Bromide and 20 drops of Ipatropium Bromide diluted for a total of up to 3 ml of saline solution 0.9%. A MESH vibrating nebulizer (NIVO, Philips Respironics, Murrysville, Pennsylvania) will be used.
|
Experimental: Positive expiratory pressure valve Intervention, will perform nebulization associated with positive expiratory pressure valve in the airways (EPAP) |
Device: Positive expiratory pressure valve
For nebulization associated with the EPAP valve will be used a non-invasive distribution system consisting of a non-toxic orofacial mask connected to a spring loaded EPAP valve. This mask will be secured to the patient's face through tabs in order to prevent leakage and to maintain proper pressurizing and better patient adaptation.
|
Experimental: Nonivasive ventilation intervention, will perform nebulization associated with non-invasive ventilation Bi-level mode; |
Device: Nonivasive ventilation
For nebulization associated with NIV, a noninvasive distribution system consisting of a non-toxic orofacial mask connected to the NIV circuit will be used, and the latter will be being fed by a radioaerosol flow generated by a nebulizer coupled to the circuit. This mask will be secured to the patient's face through tabs in order to prevent leakage and to maintain proper pressurizing and better patient adaptation.
|
Outcome Measures
Primary Outcome Measures
- Change of Pulmonary Function [30 minutes after intervention]
Pulmonary function test performed through spirometry
- Change of Aerosol deposition in the lungs [Immediately after intervention]
The pulmonary deposition index (PPI), expressed in percentage terms and obtained by the ratio of the number of counts of each ROI to the total number of counts of the respective lung.
- Change of Regional pulmonary ventilation [30 minutes after intervention]
The impedance variation (AZ) and regional pulmonary ventilation (ZEE) will be evaluated for each region of interest.
Secondary Outcome Measures
- Change of Ventilatory pattern [30 minutes after intervention]
Respiratory rate, tidal volume, minute volume, inspiratory time, expiratory time, and total time.
- Change of Heart Rate [30 minutes after intervention]
Heart Rate
- Change of Peripheral Oxygen Saturation [Immediately and 30 minutes after intervention]
Peripheral Oxygen Saturation
Eligibility Criteria
Criteria
Inclusion Criteria:
- Patients with stage II (moderate) and III (severe) COPD according to the guidelines of the Global Initiative for Chronic Obstructive Lung Disease (GOLD)
Exclusion Criteria:
- unable to understand or perform procedures that present rheumatic or orthopedic diseases or deformities / abnormalities in the spine that compromise the mechanics of the respiratory system; respiratory comorbidities such as asthma, bronchiectasis and sequela of tuberculosis, cardiovascular and neurological comorbidities; hemodynamic instability defined as heart rate greater than 150 bpm, or systolic pressure less than 90 mmHg; hypertension (blood pressure> 149/89 mmHg) or hypotension (blood pressure <90/60 mmHg) at the time of collection; pregnancy or suspected pregnancy; and any contraindications for the use of PEP.
Contacts and Locations
Locations
Site | City | State | Country | Postal Code | |
---|---|---|---|---|---|
1 | Department of Physical Therapy, Federal University of Pernambuco, Recife, Pernambuco, Brazil | Recife | Pernambuco | Brazil | 50670-901 |
Sponsors and Collaborators
- Universidade Federal de Pernambuco
Investigators
- Principal Investigator: Catarina Rattes, Universidade Federal de Pernambuco
Study Documents (Full-Text)
None provided.More Information
Publications
None provided.- UFPE_FISIO_RESP